ArticleInternational journal of surgery (London, England)2026
Efficacy and safety of 1470-nm diode laser enucleation of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benign prostatic hyperplasia (BPH) is a common urological condition in aging men, often requiring surgical intervention when medical therapy fails. The 1470-nm diode laser enucleation of the prostate (DiLEP) has emerged as a promising technique, but its efficacy and safety remain to be systematically evaluated. Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library to identify randomized controlled trials (RCTs) investigating 1470-nm DiLEP in the treatment of BPH. Primary outcomes included functional parameters such as International Prostate Symptom Score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary outcomes included intraoperative and perioperative indicators (e.g., operative time, hemoglobin decrease, catheterization duration, bladder irrigation time) and complication rates. Effect sizes were synthesized using appropriate fixed- or random-effects models based on heterogeneity, and reported as mean difference (MD) or odds ratios with 95% confidence intervals. Results: Four RCTs involving 533 patients were included. 1470-nm DiLEP was associated with significantly shorter operative time (MD = -24.43, P < 0.0001), reduced hemoglobin loss (MD = -2.77, P = 0.02), shorter bladder irrigation time (MD = -13.23, P < 0.0001), and reduced catheterization duration (MD = -2.29, P < 0.0001). Functional outcomes such as IPSS, QoL, and Qmax were comparable between groups, but DiLEP showed superior reduction in PVR at 6 and 12 months. No significant differences in complication rates were observed. Conclusion: The 1470-nm DiLEP appears to be a safe and effective surgical option for BPH, with advantages in perioperative outcomes and potential mid-term functional benefits, particularly in improving bladder emptying. Further large-scale, long-term RCTs are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.